CTLA4 and melanoma: In melanoma, eosinophils are considered one of the most promising cellular biomarkers for post-ICI cancer treatment and may even be effector cells in the terminal stage, especially for anti-CTLA4 and anti-PD-1 antibodies 44, 45.